Jaguar Health Hosts Symposium on Management of Diarrhea Related to Cancer Therapy

Jaguar Health subsidiary Napo Pharmaceuticals’ Prearranged Testing addition of international sites, targeting completion of enrollment in Q2 2023

SAN FRANCISCO, CA / AccessWire / November 21, 2022 / Jaguar Health, Inc. (NASDAQ: JAGX) and its wholly owned subsidiary Nepo Pharmaceuticals (Nepo) today announced that Nepo will host a hybrid symposium on November 18, 2022 titled Management of cancer therapy-related diarrhea: is it time for a paradigm shift? The symposium featured presentations by leading oncology and infectious disease experts and discussed the impact of cancer therapy-related diarrhea (CTD) as well as the unmet need for CTD burden based on current management guidelines.

Symposium Prophylaxis of diarrhea in cancer patients as a paradigm-shift to reduce the impact of CTD on activities of daily living (ADLs), dose reduction, and/or discontinuation of cancer therapy and overall improvement of quality of life The need for (QoL) of cancer patients receiving targeted therapy with or without standard chemotherapy. Additionally, the panel discussed the results of a recently published prophylactic study in breast cancer patients receiving trastuzumab, pertuzumab, and a taxane with or without crofelemer (HALT-D) and those evaluating safety and efficacy. Characteristics of an ongoing Phase 3 pivotal clinical study of crofelemer as prophylaxis for CTD in adult patients with solid tumors receiving targeted therapy with or without standard chemotherapy (Protocol NP303-102; OnTarget Study) . The symposium was attended individually by some of the investigators of the On-Target study as well as investigators from various clinical sites within and outside the United States.

Praveen Chaturvedi, PhD, Napo Pharmaceuticals’ and Jaguar Health’s Chair of the Scientific Advisory Board, said, “We were very pleased with the level of participation in this first symposium to discuss the management of CTDs and the neglected burden of CTDs on cancer patients. ” and Chief Scientific Officer. “We are grateful to the clinical and scientific leaders of the oncology community who joined us to discuss the limitations of CTD management guidelines and the potential impact of crofelemer for the prophylaxis of CTD. Symposium Contents Current and Future Clinical ​will provide investigators with more background on the value of prophylaxis of CTD as being studied in the pivotal on-target trial.”

Speakers and panelists at the symposium included faculty members from academic institutions and private clinics, as well as NAPO’s clinical leadership team:

  • Pablo C. Ochuysen, MD: Professor of Medicine, Division of Infectious Diseases, Infection Control and Employee Health, Department of Internal Medicine, MD Anderson Cancer Center at The University of Texas, Houston, Texas.

  • Lee Schwartzberg, MD, FACP: leading breast cancer medical oncologist and hematologist who serves as chief of medical oncology and hematology at Renoun Health-William N. Pennington Cancer Institute in Reno, NV; former executive director, West Clinic, Memphis, TN.

  • Eric Roland, MD, FAAHPM: Assistant Professor of Medicine, Department of Hematology/Medical Oncology, School of Medicine, Oregon Health & Science University; Former Assistant Professor of Medicine, Massachusetts General Hospital, Harvard Medical School.

  • James T. D’Olimpio, MD, FACP, FAAHPM: Principal Investigator/Advisor, Clinical Research Alliance, Westbury, NY; Formerly director of assistant oncology/cancer pain and symptom management at North Shore University Hospital, and assistant professor of medicine at Hofstra/North Shore-LIJ School of Medicine.

  • Paula Polman, MD, PhD: Associate Professor, MD Anderson Cancer Center.

  • Praveen Chaturvedi, PhD: Chairman and Chief Scientific Officer of Nepo Pharmaceuticals’ and Jaguar Health’s Scientific Advisory Board.

  • Darlene Horton, MD: Chief Medical Officer of Napo Pharmaceuticals.

  • Alison Schier, MD: Vice President of Clinical Research and Medical Affairs, Napo Pharmaceuticals.

About diarrhea related to cancer therapy

A significant proportion of patients undergoing cancer treatment experience diarrhea, and diarrhea has the potential for dehydration, potential infection, and non-adherence to treatment in this population. Novel “targeted cancer therapy” agents, such as epidermal growth factor receptor (EGFR) antibodies and tyrosine kinase inhibitors (TKIs), with or without cycle chemotherapy agents, can increase the amount of electrolyte and fluid in the lumen of the intestine, thereby Resulting loose/watery stool (i.e., diarrhea). Diarrhea has been reported as one of the most common side effects of TKIs and may result in cancer therapy drug discontinuation or reduction in therapeutic doses, potentially affecting patient outcome. Diarrhea is also a common side effect of some approved CDK 4/6 inhibitors.

about crofelmar

Croflemer is a new, oral plant-based drug purified from the sap of red bark, also known as “dragon’s blood”. croton leclery Trees in the Amazon rainforest. Napo Pharmaceuticals has established a sustainable harvesting program under fair trade practices for crofflemer, to ensure a high level of quality, ecological integrity and support for indigenous communities.

About Jaguar Health, Napo Pharmaceuticals, Napo Therapeutics and Jaguar Animal Health

Jaguar Health, Inc. is a commercial-scale pharmaceuticals company focused on the development of novel, plant-based, non-opioid and sustainably derived medicines for people and animals with GI distress, including chronic, debilitating diarrhea. A wholly owned subsidiary of Jaguar Health, Napo Pharmaceuticals, Inc. focuses on the development and commercialization of proprietary plant-based human pharmaceuticals from plants responsibly harvested from rainforest regions. Our croflemer drug product is the subject of the ONTARGET study, an ongoing pivotal Phase 3 clinical trial for the prophylaxis of diarrhea in adult cancer patients receiving targeted therapy. Jaguar Health is the majority shareholder of Napo Therapeutics SpA (f/k/a Napo EU SpA), an Italian corporation established by Jaguar Health in Milan, Italy in 2021 with a focus on expanding access to Croflemer in Europe. Jaguar Animal Health is a trade name of Jaguar Health.

For more information about Jaguar Health, please visit For more information about Napo Pharmaceuticals, visit

forward-looking statements

Certain statements in this press release constitute “forward-looking statements”. In some cases, you can use “may,” “will,” “should,” “expect,” “plan,” “aim,” “anticipate,” “might,” “intend,” “goal,” ” project,” “anticipate,” “believe,” “anticipate,” “predict,” “potential” or “continue” or the negative of these terms or other similar expressions. The forward-looking statements in this release are predictions only. Jaguar has based these forward-looking statements largely on its current expectations and assumptions about future events. These forward-looking statements speak only as of the date of this release and are subject to a number of risks, uncertainties and assumptions, some of which cannot be predicted or quantified and some of which are beyond Jaguar’s control. Except as required by applicable law, Jaguar does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of new information, future events, changed circumstances or otherwise.


peter hodge
Jaguar Health, Inc.
[email protected]

Source: Jaguar Health, Inc.

View the source version on

Leave a Comment